Sodium Clodronate

Sodium Clodronate is a bisphosphonate. It inhibits bone resorption without affecting absorption. Sodium Clodronate is also used as an adjunct in the treatment of severe hypercalcemia. Common adverse effects include gastrointestinal disturbances.

Sodium Clodronate is primarily indicated in conditions like Hypercalcemia, Hypercalcemia associated with malignancy, Osteolytic bone metastases, Osteolytic lesions.

Sodium Clodronate is contraindicated in conditions like Renal insufficiency.

Sodium Clodronate produces potentially life-threatening effects which include Acute Renal Failure. which are responsible for the discontinuation of Sodium Clodronate therapy. The signs and symptoms that are produced after the acute overdosage of Sodium Clodronate include Acute renal failure. The symptomatic adverse reactions produced by Sodium Clodronate are more or less tolerable and if they become severe, they can be treated symptomatically, these include Nausea, Vomiting, Flushing, Hypocalcemia.

NSAIDs should not be used concurrently with OSPHOS. Concurrent use of NSAIDs with OSPHOS may increase the risk of renal toxicity and acute renal failure. Human Warnings: Not for human use. Keep this and all drugs out of the reach of children. Consult a physician in case of accidental human exposure.

NSAIDs should not be used concurrently with OSPHOS. Concurrent use of NSAIDs with OSPHOS may increase the risk of renal toxicity and acute renal failure. Human Warnings: Not for human use. Keep this and all drugs out of the reach of children. Consult a physician in case of accidental human exposure.

800 mg (800 (800)) 12 hourly PO — The capsules should be taken with a little fluid, but not milk, at least 1 hour before or 1 hour after food. If necessary, the dose may be increased but should not exceed a maximum of 3200 mg sodium clodronate daily. Scraped Dose — Clinical improvement is most evident at 2 months post-treatment (see EFFECTIVENESS ). Of the horses that responded to treatment with OSPHOS in the field study, 65% maintained their level of improvement through the 6 month evaluation. If there is no response to initial therapy, the horse should be re-evaluated. For horses that initially respond to OSPHOS but do not maintain their clinical improvement for 6 months, OSPHOS may be re-administered at 3 to 6 month intervals based on recurrence of clinical signs. For horses that respond to OSPHOS and maintain clinical improvement for 6 months, OSPHOS should be re-administered after clinical signs recur.

No child dosage information is recorded for this medicine yet.

No neonatal dosage information is recorded for this medicine yet.

No data regarding the interactions of Sodium Clodronate was found.

Inj, caps Store at room temperature, . Protect from Sunlight, Moisture and Heat.